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SEVERE COMBINED IMMUNODEFICIENT MICE
Excellent large animal models exist for accepting human 
stem cell xenografts in utero (1−6) and for studying engraft-
ment of nonhuman primate (7−16) and canine stem cells 
(17−19). However, the use of the immune-deficient mouse as 
a recipient of the human stem cell graft is the most common 
and cost-effective strategy available to most laboratories. One 
of the first strains of immune-deficient mice to be used as a 
recipient of human hematopoietic cells was the severe com-
bined immunodeficient (SCID) strain (20,21). SCID mice 
have defects in T and B cell development due to a mutation 
in the gene for DNA-dependent protein kinase (DNA PK) 
on chromosome 16 (22). The DNA PK gene is required for 
successful rearrangement of T cell receptor (TCR) and im-
munoglobulin gene segments, and without it, murine T and 
B lymphocytes cannot develop. The SCID mutation also con-
fers extreme radiosensitivity, due to the inability of affected 
cells to mediate repair of double-strand breaks (22−26). A 
drawback to the use of SCID mice is that, in spite of their lack 
of T and B cells, they do have high natural killer (NK) cell 
levels. Therefore, this strain is acceptable for implantation of 
solid tissues, such as fetal thymus or sections of tumor, but 
single-cell suspensions can be rapidly recognized and lysed 
by the murine NK cells.
The hu-PBL-SCID xenograft model was created by trans-
planting human peripheral blood into SCID mice (21,27−29). 
In spite of the high NK cell levels in SCID mice, a portion 
of the human cells did engraft. However, the human cells 
that had undergone prior thymic selection in the human do-
nor became profoundly anergic in the mice (27). Human T 
lymphocytes recultured from hu-PBL-SCID mice could not 
respond to antigen stimulation for as long as 15−40 days after 
removal from the mice (27). Tary-Lehman et al. proposed 
that in the hu-PBL-SCID model, the continuous stimulation 
of antimouse-reactive human T lymphocytes leads to the 
exhaustion of the response, resulting in peripheral tolerance 
or anergy (28,29). The induction of anergy may also be due 
to the fact that murine β-2 microglobulin (β2M), associated 
with the type 1 major histocompatibility complex, cannot be 
recognized as a stimulatory signal by human T cells (30−32). 
Thus, the human T cells may exist in a state of partial activa-
tion resulting in anergy in the mice, when supporting human 
thymic tissue and antigen-presenting cells are not present.
To allow studies of functional immunity, an excellent 
model, the SCID/hu mouse, was then developed by implant-
ing fragments of human fetal liver and fetal thymus under 
the renal capsule of SCID mice (33,34). The fetal liver acts 
as a source of hematopoietic stem cells that mature in the 
human thymic fragments. In contrast to the hu-PBL-SCID 
system, SCID/hu mice have continued production of human 
T lymphocytes from stem cells within the human fetal liver 
(34−36). The human T lymphocytes do not cause graft-vs.-
host disease (GVHD), perhaps because they have undergone 
positive and negative selection in the human thymus and see 
the murine tissue antigens as “self,” since murine dendritic 
and other antigen-presenting cells colonize the human thy-
mus. Human CD3+ cells recovered from SCID/hu thy/liv 
mice can be readily stimulated by mitogens or anti-CD3 anti-
bodies, suggesting tolerance in vivo rather than anergy (34). 
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Adult human CD34+ cells can also be infused into the fe-
tal thymus fragment in SCID/hu mice and can subsequently 
mature to functional T cells (37).  The SCID/hu thy/liv sys-
tem is the best xenograft model of human T cell development 
that can be used currently to study functional immunity. 
However, drawbacks to the use of the SCID/hu model are the 
need to obtain human fetal tissues, which are not available to 
all laboratories, and the requirement for surgical skill to place 
the fetal tissues under the murine kidney capsule. In prelimi-
nary experiments, the transplantation of postnatal, rather than 
fetal, thymus sections into the muscles of immune-deficient 
mice was not as successful (X. Wang, R. Hong, and J. Nolta, 
unpublished data). In addition, the lack of large numbers 
of developing human T cells precludes the performance of 
some types of studies in SCID/hu mice. Therefore, enhanced 
models for human T lymphocyte generation or engraftment in 
immune-deficient mice are still sought.
NOD/SCID MICE
An improved xenograft recipient, the nonobese diabetic 
SCID [(NOD/LtSz-SCID/SCID (NOD/SCID)] mouse, was 
initially derived from the SCID strain by Shultz and col-
leagues at The Jackson Laboratory (Bar Harbor, ME, USA). 
Now the most prevalently used strain of immune-deficient 
mouse, NOD/SCID mice have an excellent capacity to 
engraft with human cells due to additional defects in NK 
cell and macrophage function and circulating complement 
(38,39). The mice must be kept in a clean barrier facility be-
cause of their extreme immune deficiencies but are very easy 
to breed, with large robust litters. Transplanted human stem 
cells primarily generate B lymphocytes in the NOD/SCID 
microenvironment, CD34+ cells are retained, and myeloid 
cells develop to a lesser extent than B lymphocytes. Human 
T cells are not generated from highly purified stem cells in 
adult NOD/SCID mice. Mature human T cells can survive in 
some cases and undergo peripheral expansion, especially if 
extremely high cell numbers are transplanted (40).  
There have been reports that human T cells can be found in 
the spleen, thymus, and lymph nodes of NOD/SCID mice one 
month after transplantation with unseparated umbilical cord 
blood cells (41). These cells may have arisen from peripheral 
expansion. NOD/SCID mice are an excellent system in which 
to study human B lymphocyte development, but there are few 
reports of human T cell development from purified stem cells 
in NOD/SCID mice, under normal transplant conditions. We 
and others have been unable to achieve T cell development in 
NOD/SCID mice, using 99.5% pure CD34+/CD38- cells from 
human bone marrow or umbilical cord blood, potentially due 
to the presence of residual NK cells in NOD/SCID mice (30). 
Another problem might be that the acellular murine thymic 
microenvironment could be too atrophied to allow cell seed-
ing and development, by the time that human stem cells are 
injected into the NOD/SCID recipients. These questions re-
main to be answered.
Civin’s group recently described a model for GVHD using 
NOD/SCID mice as recipients for mature human T cells (40). 
Human T cells were recovered, and a GVHD-like disease 
was observed only when high cell doses were transplanted 
(40). In many cases, however, even mature T lymphocytes in 
transplanted human PBL or cord blood samples can be rap-
idly cleared from NOD/SCID mice by unknown mechanisms. 
Leakiness for NK cells appears to be a prime factor in human 
T cell rejection in xenograft models, particularly the NOD/
SCID (42). In their study, the treatment of NOD/SCID mice 
with an antimurine interleukin-2R beta (IL-2R β) antibody, 
previously shown to decrease NK cell activity, resulted in 
functional human T cells recovered from 60% of the treated 
mice, in contrast to sporadic low levels in the untreated mice 
(42). 
Although human T cells do not develop well following 
transplantation of purified hematopoietic stem cells into un-
treated NOD/SCID recipients, interestingly, the fetal thymus 
organ culture (FTOC) works well when the thymic lobes are 
harvested from fetal NOD/SCID mice. FTOC is a method 
to develop T lymphocytes from human stem and progenitor 
cells, in murine fetal thymic lobes grown at the liquid/air 
interface. Traditionally, the murine fetal thymic lobes must 
be depleted of murine thymocytes by extended culture prior 
to introduction of the human cells. Laure Coulombels’ group 
described a more simplified technique, in which NOD/SCID 
fetal thymic lobes are used immediately after harvest, due to 
the absolute lack of murine thymocytes (32). This system 
has proven to be very reproducible for generating human T 
lymphocytes from small numbers of highly purified human 
pluripotent stem cells, which rules out peripheral expansion 
of mature T cells.
The NOD/SCID strain is by far the most widely used 
xenograft recipient to date. However, one drawback to the 
use of NOD/SCID mice is their shortened lifespan (often 
4−6 months) due to the presence of a provirus, Emv-30, on 
chromosome 11, that causes thymoma (39,43). The duration 
of the experiments that can be done to examine human stem 
cell engraftment using NOD/SCID mice is therefore limited. 
Some of the mice do live to old age, but others in each arm of 
the experiment are lost to early thymoma. Therefore, if many 
mice are initially transplanted per arm of each experiment, it 
is possible to obtain some long-term survivors for analysis 
out to 6 months posttransplantation. Many groups also use 
NOD/SCID mice as recipients for human stem cells for 1−2 
months, followed by a secondary transplant into the same 
strain, for several more months (41,44−46).
The NOD/SCID strain was the first to be used to show that 
human CD34- cells could have engraftment capacity (47,48). 
This field has been interesting yet controversial. Osawa et al. 
initially reported a murine CD34- cell that had full engrafting 
capacity (49). In the same year, Goodell et al. characterized a 
primitive “side population” (or SP) cells in mouse, monkey, 
and man, that excluded the Hoechst 33342 dye, lacked CD34 
expression, and had reconstitution capacity (50,51). Bhatia et 
al. next demonstrated that there was a low level of engraft-
ment and hematopoietic capacity in human CD34- cells 
injected into NOD/SCID mice (52), and Fujisaka et al. con-
firmed this finding (53). 
In those initial studies, the levels of engrafting CD34- cells 
were extremely low in the NOD/SCID mice. Nakamura et al. 
later demonstrated that preculture of the human CD34- cells 
1264 BioTechniques                                                                                                                                                                                         Vol. 35, No. 6 (2003)
REVIEW
STEM CELLS: BIOLOGY AND TECHNOLOGY FOR THE FUTURE
Vol. 35, No. 6 (2003)                                                                                                                                                                                         BioTechniques 1265
with cytokines in vitro prior to transplantation greatly in-
creased their capacity for homing and engraftment (54). Other 
groups who infused unstimulated human CD34- cells saw little 
to no engraftment (55). Sato et al. hypothesized that the CD34- 
stem cells are extremely quiescent, and that some type of acti-
vation is required to cause up-regulation of CD34 expression, 
and to induce the capacity to engraft a recipient mouse (56). In 
the studies by their group, that activation was promoted by in 
vivo treatment of donor mice with 5-FU. These studies dem-
onstrated that CD34- cells can generate CD34+ cells, and that 
stimulation of the quiescent CD34- stem cells was necessary to 
allow engraftment into recipient mice.
More recently, our group used the NOD/SCID strain as 
secondary recipients in studies of human CD34 reversibility. 
We initially identified and functionally characterized a popu-
lation of human CD45+/CD34- cells that was recovered from 
the bone marrow of the long-lived immune-deficient beige/
nude/xid (BNX) mice 8−12 months after transplantation of 
highly purified human bone marrow-derived CD34+/CD38- 
stem/progenitor cells (57−59). The human CD45+ cells were 
devoid of CD34 protein and mRNA when isolated from the 
mice (60). However, significantly higher numbers of human 
colony-forming units (CFU) and long-term culture-initiating 
cells (LTCIC) per engrafted human CD45+ cell were recov-
ered from the marrow of BNX mice than from the marrow of 
human stem cell-engrafted NOD/SCID mice, where 24% of 
the human graft maintained CD34 expression. In addition to 
their capacity for extensive in vitro generative capacity, the 
human CD45+/CD34- cells recovered from the BNX bone 
marrow were determined to have secondary reconstitution 
capacity and to produce CD34+ progeny following retrans-
plantation into the NOD/SCID recipients (60). These studies 
demonstrate that the human CD34+ population can act as a 
reservoir for generation of CD34- cells, which can, in turn, 
regenerate CD34+ cells. Expression of CD34 was therefore 
shown to be reversible on reconstituting human hematopoi-
etic stem cells.
In follow-up experiments, it was determined that human 
CD34+/CD38- cells do retain CD34 expression for up to 4 
months in BNX recipients. Therefore, it appears that the ex-
pression of CD34 may have been lost over time in the mice, 
perhaps as the human cells in the murine marrow became 
very quiescent. This data would agree with a seminal report 
from Makio Ogawa’s group, who showed that in murine 
stem cells, CD34 expression reflects the activation state of 
hematopoietic stem cells and that this is reversible. Ogawa’s 
group hypothesized that up-regulation of CD34 expression in 
the murine system is an “activation event” (56). The activa-
tion to which Ogawa and colleagues refer is not likely to be 
simply cell cycle induction, since both murine and human 
hematopoietic cells can be identified that express high levels 
of CD34, yet are very highly quiescent (59,61). The molecu-
lar nature of the activating factors that regulate induction of 
CD34 expression in the 5-fluoruracil (5-FU)-treated mice 
described by Sato et al. (56) remain unknown at the cur-
rent time. Whether CD34 is up-regulated by an increase in 
metabolic activity as the quiescent cells progress toward cell 
cycle by down-regulation of cyclin-dependent kinase (CDK) 
inhibitors and induction of cyclins and cell cycle regulatory 
proteins (62), or whether one or both progeny from the initial 
divisions of a CD34- cell acquire CD34 expression, is not 
yet clearly defined. This question is currently a subject of 
investigation in several laboratories, using both in vitro and 
immune-deficient mouse xenograft systems. As with many 
other areas of research requiring engraftment of primitive 
hematopoietic stem cells, the NOD/SCID mouse is the strain 
most commonly used in studies of CD34 expression.
NOD/SCID/β-2 MICROGLOBULIN NULL MICE
NOD/SCID/β2M null mice have a more absolute immu-
nodeficiency than the NOD/SCID strain and have virtually no 
NK cell function (63). They are very permissive for xenograft 
acceptance (64,65). Committed progenitor populations, as 
well as primitive stem cells, can engraft in NOD/SCID/β2M 
null mice (63,66,67). Unfortunately, although it is the best 
and most consistent murine xenograft model, in our experi-
ence, the NOD/SCID/β2M null strain also has a lifespan that 
is even shorter than the NOD/SCID strain, due to the early 
development of thymoma (39,43). The lifespan may be even 
shorter than in the NOD/SCID parental strain, potentially 
due to duplication of the lethal provirus to additional chro-
mosomes, or perhaps the more profound NK cell deficiency. 
However, this strain appears to be permissive for human T 
cell development, in addition to B and myeloid lineages, and 
can accept more mature progenitor populations in addition to 
stem cells, so is well worth working with. Breeding is difficult 
because the female mice often die from thymoma before they 
can rear their first batch of pups. To combat the problem of 
female breeders dying before the first or second litter can be 
raised to maturity, we and other groups routinely foster pups 
to clean but immune-competent mothers that consistently live 
long enough to raise the pups to the weaning stage.
A xenograft assay based on “conditioned newborn” NOD/
SCID or NOD/SCID/β2M null mice was developed that al-
lows longer term in vivo engraftment from human umbilical 
cord blood cells than the standard assays, in which mice are 
transplanted at 6−12 weeks of age (68). Four to five months 
after transplantation, multilineage engraftment was demon-
strated by flow cytometry and by the growth of multilineage 
colonies in methylcellulose culture. Secondary transplanta-
tion of the isolated human CD45+ cells, also performed at 
4−5 months posttransplantation, showed that human stem 
cells had durably engrafted the newborn pups, following con-
ditioning by busulfan and cyclophosphamide, but no radia-
tion (68). This method, combined with fostering the newborn 
and transplanted pups to allow survival of the nursing mother 
while the pups mature, is an excellent example of modifying 
experimental strategies to compensate for the limitations of 
the xenograft model. The NOD/SCID/β2M null strain allows 
the highest and most reproducible engraftment with human 
cells to date, and is only limited by its short lifespan.
BEIGE/NUDE/XID MICE
The BNX mouse was the immune-deficient strain first 
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reported to accept a human hematopoietic progenitor xeno-
graft, by Kamel-Reid and Dick in 1988 (69). The BNX mice 
are triple recessive mutant immune-deficient mice with a 2-
year lifespan and deficiencies in T, B, and NK cells. Previous 
studies had examined human cell lines and solid tumors in 
nude mice, but since nude mice have high NK cell levels to 
compensate for their lack of T cells, a transplantation of a sin-
gle-cell suspension of human hematopoietic cells would be 
rapidly rejected. Another problem that had prevented the field 
of human-to-murine xenotransplantation from progressing 
prior to 1988 had been the lack of cytokines cross-reactive to 
human stem cells in the mice. Kamel-Reid et al. described the 
BNX/hu model, in which the immune-deficient mice were 
injected with human interleukin 3 (IL-3), and human pro-
genitors could survive for several months, with a primarily 
myeloid differentiative capacity (69).
To avoid costly injections of cytokines every 48 hours 
as previously described (69), our group co-transplanted hu-
man mesenchymal stem cells (MSCs) engineered to secrete 
human IL-3, in addition to their endogenous human growth 
factors (70). We had previously referred to the CD45+ cell-
depleted, expanded, adherent myofibroblastic layer from the 
marrow as “stroma,” but the better term, mesenchymal stem 
cells, reflects their capacity to differentiate into multiple 
tissues (71−73). It is also of interest that MSCs  have been 
reported to enhance engraftment of hematopoietic stem cells 
(70,74−76), and to suppress an immune reaction (77,78). 
Therefore, in retrospect, the co-transplantation of human 
mesenchymal stem cells with the hematopoietic stem cells 
in our BNX/hu xenograft system may have been important 
for reasons other than IL-3 production, since the BNX mice 
can be leaky in their B cell deficiency and can also generate T 
cells through extrathymic production. Yet, in spite of the leak-
iness of their immune systems, BNX mice have been quite 
useful as xenograft recipients because they provide one of 
the few models in which transplanted human hematopoietic 
cells or tumors can be followed long term (79−83), due to the 
normal lifespan of the mice, in contrast to the short lifespan 
of NOD/SCID mice.
BNX mice are useful for detecting loss or alteration of 
specific lineages or engrafting stem cell populations, fol-
lowing in vitro manipulation, due to their normal lifespan. 
Sustained multilineage human hematopoiesis in BNX mice 
can be achieved from transplanted CD34+ and CD34+/CD38- 
progenitors. The presence of human myeloid/erythroid colo-
ny-forming progenitors, mature myeloid B cells, and T lym-
phoid cells can be demonstrated in the marrow of the mice 
for up to 18 months. Our group capitalized on this extended 
engraftment capacity to examine methods to optimize trans-
duction and ex vivo culture of primitive human stem cells. We 
demonstrated that engrafting cells are best cultured with the 
ability to engage integrins on a stromal monolayer (76) or a 
purified fibronectin (FN) fragment (84), to sustain the capac-
ity for long-term hematopoiesis. In more recent studies, we 
used the BNX/hu system to show that the engrafting human 
stem cell pool is maintained on FN and has sustained expres-
sion of GATA-2, c-Myb, and CD34, as opposed to cells that 
have only short-term engraftment capacity following suspen-
sion in culture (84a). We used the BNX system to determine 
that FLT3 ligand could partially overcome the late graft 
failure that occurred in human bone marrow-derived hemato-
poietic stem cells cultured in suspension (85). Our group also 
used the BNX system to study effects of cytokines on altering 
lineage production in vivo (86,87). Therefore, the BNX/hu 
xenograft system is a sensitive method to assess the capacity 
of marrow and umbilical cord blood-derived stem cells to un-
dergo multilineage, long-term differentiation in vivo. 
Transplantation of human hematopoietic progenitor cells 
from mobilized peripheral blood mononuclear cells, adult 
bone marrow, and fetal bone marrow, were done by Turner 
et al. to evaluate the capacity of each progenitor source to 
produce multilineage human hematopoietic engraftment in 
BNX mice (88). Fetal progenitors were found to have the 
best engraftment capacity, and all lineages of blood cells, in-
cluding T lymphocytes, were produced from the transplanted 
stem/progenitor cells in the BNX mice.
Human T lymphocytes develop from transplanted hema-
topoietic stem cells in the bone marrow and livers of athymic 
BNX mice. The T cells are of the phenotypes CD3+/CD4+, 
CD3+/CD8+, or “double positive” CD3+/CD4+/CD8+. They 
all express TCR αβ, and the Vβ repertoire is severly skewed 
(86). The levels of CD3+/CD8+ cells almost always exceed 
the levels of CD3+/CD4+ cells (86,87,89). These data are in 
agreement with that of Mackall et al., who demonstrated that 
regeneration of murine CD8+ cells occurs more readily than 
CD4+ cell regeneration after transplantation in athymic mice 
(90). Human T lymphocytes that develop by extrathymic 
mechanisms are normally anergic following recovery from 
the bone marrow of the BNX mice (87). The cells do not 
respond well to stimulation in vitro after recovery from the 
marrow. Co-transplantation of human interleukin 7 (huIL-7)-
secreting human MSCs in BNX mice significantly increased 
the levels and activation status of human CD4+ cells that re-
generated in the bone marrow of athymic BNX mice, to the 
levels seen in normal human PBL (87).
Our group used the capacity of BNX mice to develop T 
lymphocytes from transplanted purified human hematopoi-
etic stem cells to document that stem cells capable of generat-
ing both T lymphoid and myeloid cells could arise from the 
same, retroviral vector-transduced hematopoietic stem cell 
(89). This data was obtained using the inverse PCR method 
of clonal integration analysis before the more popular NOD/
SCID strain, discussed below, was widely available. Now, a 
more common strategy using the NOD/SCID strain, which 
generates human B but not T lymphocytes from purified stem 
cells with normal transplantation methods, is to document 
production of both B lymphoid and myeloid progenitors aris-
ing from the same stem cell (91).
One advantage to the use of BNX mice, in addition to 
their 2-year lifespan, is that they lack the radiation sensitiv-
ity that is a constant problem with the most commonly used 
xenograft strain, the NOD/SCID mice. NOD/SCID mice 
cannot repair double-strand DNA breaks due to a mutation 
in the gene for DNA PK. BNX mice do not have the SCID 
mutation in DNA PK and recover from sublethal radiation 
as quickly as normal mice, if kept on low-dose antibiotics in 
strict barrier conditions. However, BNX mice are difficult to 
breed, since only females heterozygous at the nude allele can 
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be used, and their B cell defect is sometimes leaky, so each 
recipient mouse must be screened prior to use. To avoid these 
problems, we developed a novel immune-deficient mouse 
strain, the nude/NOD/SCID mouse.
NUDE/NOD/SCID MICE
As discussed earlier in the review, the NOD/LtSz-SCID/
SCID (NOD/SCID) strain (38) is the most common immune-
deficient mouse xenograft strain used to date. The mouse 
is relatively hardy, breeds well, and can be engrafted with 
human hematopoietic cells to very high levels, with up to 
90% of the marrow replaced, if human umbilical cord blood 
is transplanted. However, a major drawback to the use of the 
NOD/SCID strain, in addition to their radiation sensitivity, is 
that their average lifespan is short, due to the presence of the 
provirus Emv-30 on chromosome 11. Our group hypothesized 
that, by bringing two copies of the nude gene (also on chro-
mosome 11) into the NOD/SCID background, the provirus, 
and thymic tissue where the thymoma arises would be elimi-
nated from homozygous nu/nu NOD/SCID mice. We there-
fore extensively backcrossed nude and NOD/SCID mice over 
a period of three years, monitoring for immunodeficiency 
and carrying the nude gene. Nude progeny were backcrossed 
to NOD/SCID females for seven generations, resulting in a 
mouse that has the char-
acteristics of NOD/SCID 
mice, but lacks fur and the 
life-shortening provirus. 
The resulting nude/NOD/
SCID mice have a 2-year 
lifespan. Engraftment of 
human hematopoietic stem 
cells occurs efficiently in 
these mice, with levels 
reaching 82% marrow re-
placement (91a, 91b), as 
can be achieved with the 
NOD/SCID parental strain. 
As with many of the newer 
strains of immune-deficient 
mice, this strain is currently 
only available from the in-
vestigators that developed 
it (Nolta laboratory).
Nude/NOD/SCID mice 
do not require systemic hu-
man IL-3 to allow survival 
of the transplanted human 
cells, as our group and John 
Dick’s group have reported 
to be necessary for the 
BNX strain (69,70,89). It 
is interesting that different 
cytokine and chemokine 
levels likely exist in the 
various strains of immune-
deficient mice and can 
differentially support development of human hematopoietic 
lineages. We compared engraftment of human umbilical cord 
blood CD34+ progenitors in three strains of immune-deficient 
mice (nude/NOD/SCID, NOD/SCID, and BNX) and obtained 
highly different outcomes in human blood cell lineage surviv-
al or development, in support of this theory (Figure 1). The 
proportion of each hematopoietic lineage that develops from 
transplanted human hematopoietic stem and progenitor cells 
in all three strains differs. NOD/SCID mice generate primar-
ily human B lymphocytes from transplanted human CD34+ 
cells, while human cells of all myeloid lineages and B and T 
lymphocytes develop in the bone marrow of BNX mice co-
transplanted with human bone marrow CD34+ and CD34+/
CD38- progenitors and IL-3 producing MSCs, as described 
above. Nude NOD/SCID mice are athymic. Therefore, as 
with the BNX mice described above, only extrathymic hu-
man T cell development is possible. These extrathymically 
developed human T cells are abnormal, as we have shown in 
the BNX strain (91c). Nevertheless, the nude/NOD/SCID is 
one of the few immune-deficient mouse strains where mature 
human T cells survive following injection. 
In recent studies, we used the nude/NOD/SCID strain 
in comparison to the NOD/SCID strain to study tracking of 
adipose-derived mesenchymal stem cells (AMSCs) into vari-
ous tissues. There was no significant difference in the tissue 
distribution observed when cells were introduced into either 
Figure 1. Lineage development from human CD34+ cells in three strains of immune-deficient mice. CD34+ progen-
itors were isolated from human bone marrow and one million cells were transplanted into mice of three different strains 
after sublethal irradiation. Between 2 and 7 months later, the mice were harvested, and lineage analyses were performed. 
The percentages of each human blood cell lineage that make up the total human CD45+ compartment are shown in the 
pie chart for each strain. BNX, beige nude xid; NOD/SCID, nonobese diabetic severe combined immunodeficient. 
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nude/NOD/SCID or NOD/SCID mice via intravenous, intra-
peritoneal, intramuscular, or subcutaneous routes. This sug-
gests that AMSCs have the ability to navigate either through 
intravenous or extravascular routes. The nude/NOD/SCID 
strain allowed a longer follow-up and more reproducible data 
at day 75 posttransplantation, when many of the NOD/SCID 
mice had to be removed from the study due to the develop-
ment of thymoma. We have not yet observed thymoma de-
veloping in nude/NOD/SCID mice, out to 2 years of observa-
tion. Nude/NOD/SCID mice therefore represent a significant 
advance over the traditional NOD/SCID in that they have the 
same engraftment capacities but their extended lifespan will 
allow long term in vivo xenograft studies that were previously 
available only in the relatively leaky BNX strain. The combi-
nation of favorable aspects of the NOD/SCID background 
crossed with the nude mouse has resulted in a mouse with a 
profound immune deficiency but not a shortened lifespan.
NOVEL STRAINS OF IMMUNE-DEFICIENT MICE
Several new strains have been reported recently and show 
great promise for the xenograft field, although they are not 
yet widely and commercially available. The newer strains are 
currently available only from the in-
vestigators who have developed them. 
Shultz et al. generated the NOD/
LtSz-Rag-1 null mouse, which lacks 
the DNA PK mutation in the SCID 
strain, and is therefore radioresistant. 
Instead, it has a mutation in the Rag1 
gene, important for lymphocyte gene 
rearrangement. Rag1-deficient mice 
cannot initiate V(D)J recombination 
in immunoglobulin and TCR genes, 
and therefore lack functional T and 
B lymphocytes. NOD/LtSz-Rag1null 
mice were also documented to be 
devoid of mature T or B cells and had 
low NK cell activity. They supported 
high levels of engraftment with hu-
man hematopoietic stem cells and 
also allowed lymphoid engraftment. 
Of interest, transplanted human T 
cells could be readily infected with 
human immunodeficiency virus. The 
mice still did develop lymphoma, 
like the NOD/SCID strain, but the 
onset was significantly delayed (92). 
The NOD/LtSz-Rag1null strain may 
therefore be suitable as xenograft 
recipients for experiments in which 
engraftment with human cells must 
progress longer than the short dura-
tion possible with NOD/SCID mice.
The Rag-2-/-/γC-/- mouse combines 
the Rag-2 knock-out with a null muta-
tion for the common gamma chain re-
ceptor, essential for signaling through 
the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors, which are 
important in lymphoid development (93,94). The mice were 
reported to have a complete absence of all T, B, and NK cell 
function and to live to a normal lifespan (under barrier condi-
tions), so should allow longer-term experimentation than the 
NOD/SCID strain (95). Goldman et al. demonstrated that in-
travenous injection of human B-lymphoblastoid cells resulted 
in earlier fatal metastatic lymphoproliferative disease than in 
NOD/SCID controls, possibly due to the fact that the Rag-2-/-/
γC-/- strain is more defective in NK cell function (93). Levels 
of engraftment with human lymphocytes were also increased, 
following injection of peripheral blood. This new strain of 
immune-deficient mice therefore has advantages over other 
existing strains for engraftment of human cells, and the ready 
acceptance of human T cells may be useful for study of adop-
tive immunotherapy and other studies of the human immune 
system.
The most recent immune-deficient mouse strain to be 
developed is the perforin (Pfp)-deficient nonobese diabetic 
(NOD)-Rag1null (NOD/LtSz-Rag1nullPfpnull) mouse (96). 
These mice are devoid of an immune system and have an av-
erage lifespan of 37 weeks. They support better engraftment 
by human peripheral blood mononuclear cells and umbilical 
cord blood cells than the NOD/LtSz-Rag1null controls. Hu-
Figure 2. Tissue localization of human adipose-derived mesenchymal stem cells (MSCs) in NOD/
SCID/MPSVII mice. Mice were transplanted intravenously with one million human adipose-derived 
MSCs following sublethal irradiation. Thirty days later, mice were anesthetized and perfused prior to tissue 
harvest. Samples of each tissue to be studied were embedded in Tissue-Tek® Optimal Cutting Temperature 
(OCT) freezing media (Sakura, Torrance, CA, USA) and frozen on liquid nitrogen. Sections were made on 
a cryotome and stained for β-glucuronidase enzyme activity using naphthol-AS-BI- β-D-glucuronide as the 
substrate. A brilliant red color was deposited over each donor-derived cell. Slides were then counterstained 
with methyl green, to allow visualization of the host cells that lack the β-glucuronidase enzyme. An ex-
ample of a kidney tissue slide stained using this method is shown. In this relatively radioresistant tissue, low 
MSC seeding efficiency is observed. NOD/SCID/MPSVII, nonobese diabetic severe combined immunode-
ficient mucopolysaccharidosis type VII.
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man engraftment is multilineage and includes progenitors and 
CD4+ T cells. Since the lack of murine NK activity seems to 
be an important factor in allowing human T cell development 
in immune-deficient mice, this new strain may be important 
for studying human immune function in a xenograft setting.
Another recently reported new immune-deficient mouse 
strain is the NOD/SCID/MPSVII mouse (97), developed 
to study the in vivo localization of xenotransplanted human 
cells. To create the strain, the β-glucuronidase (GUSB) muta-
tion of the mucopolysaccharidosis type VII (MPSVII) mouse 
was backcrossed onto the NOD/SCID strain. This new strain 
allows donor human or murine cells transplanted into the im-
mune-deficient mice to be readily visualized by a bright red 
substrate stain for the enzyme β-glucuronidase, of which they 
have normal levels. The mutant mice give no background 
for this staining, due to their enzyme deficiency. Therefore, 
any donor cell with normal β-glucuronidase levels can be 
quickly tracked in tissue slides (or a fluorescence-activated 
cell sorting-based enzyme assay) without the need for in situ 
hybridization to verify donor status. The donor cells can be 
counterstained with an immunohistochemical reaction to 
verify tissue or lineage type, after the enzymatic staining 
(97). This model will greatly facilitate studies of human and 
murine stem cell homing, tracking, and differentiation.
Our group recently used sublethally irradiated NOD/
SCID/MPSVII immune-deficient mice as recipients for 
human AMSCs. Figure 2 shows the low efficiency of the 
AMSC seeding process into kidney, examined 1 month after 
intravenous transplantation of normal human AMSCs into 
NOD/SCID/MPSVII mice. The use of this strain of mice al-
lows more rapid quantitation of the cells than was previously 
possible.  In spleen tissue, 3−4 AMSCs were detected per 10× 
field from the spleens of all mice tested. MSCs are known to 
remain in the spleen and liver for up to 6 months and release 
the protein products from retroviral vector integrants into the 
bloodstream (86). Using the rapid tracking system in NOD/
SCID/MPSVII mice, it is now possible to obtain seeding ef-
ficiencies into different tissues, without the potential artifacts 
of fluorescence in situ hybridization analyses.
NEW DIRECTIONS FOR THE 
XENOTRANSPLANTATION FIELD
The field of human to mouse xenotransplantation is con-
stantly evolving and improving. There are many aspects of 
stem cell biology that can only be studied in vivo, and there-
fore the need to make these models better and more physi-
ologically relevant for human stem cells is ongoing. A major 
current challenge is to develop a xenogeneic host that allows 
robust human T cell development from stem cells, without 
the need for implantation of human fetal tissues. This would 
allow reproducible examination of human immune function 
in laboratory mice. Another challenge is to extend the lifes-
pan of the most robustly engrafting strain, the NOD/SCID/
B2M null mouse, and/or to develop methods that allow better 
breeding efficiency for this short-lived strain. New strains 
such as a NOD/RAG/γC/WWv mouse can be envisioned, 
which might not require damaging radiation to allow human 
stem cell engraftment. As mentioned, new strains are being 
constantly generated, with The Jackson Laboratory at the 
forefront of the effort. 
The new field of “stem cell plasticity” opens an entire new 
realm of investigation, using xenograft models. Human he-
matopoietic and MSCs can be transplanted into immune-defi-
cient mice, allowing tissues that develop through transdiffer-
entiation or fusion to be analyzed in vivo. Xenograft systems 
will therefore assist in allowing the signals that regulate stem 
cell recruitment and subsequent differentiation to eventu-
ally be understood. A few of the studies already done have 
demonstrated highly purified human hematopoietic stem cell 
differentiation into hepatocyte-like cells, following liver in-
jury (98,99); have shown that rat liver oval cell-derived islet 
cell-like clusters or total murine bone marrow displayed the 
ability to reverse hyperglycemia in diabetic NOD-SCID mice 
(100,101), and also that donor murine marrow can reverse hy-
perglycemia in the same recipients (101); have demonstrated 
that human fetal-derived neurosphere cells transplanted into 
neonatal immunodeficient NOD-SCID mice proliferated, 
migrated, and differentiated in a site-specific manner (102); 
and finally, have demonstrated that human multipotent adult 
progenitor cells can engraft to multiple tissues following 
transplantation into NOD/SCID mice (103). Therefore, xeno-
transplantation systems pave the way for future studies using 
immune-deficient mice to more fully understand mechanisms 
of homing and differentiation of purified human stem cells 
of different types and from different tissues to repair injury 
of not only the hematopoietic system, but potentially also to 
contribute to the repair of damaged organs.
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